A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Clinical trial NCT03936959 · TERMINATED
Trial details
- NCT number
- NCT03936959
- Sponsor
- Eli Lilly and Company
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-24
- Primary completion
- 2020-03-30
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.